Max Kates, MD
Urology · Baltimore, MDNPI 1487910600
Payments from drug & device makers
Across 157 payments — averaging $6368.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$382K
- Seagen Inc.$275K
- Photocure Inc$129K
- Pfizer$112K
- Ferring Pharmaceuticals AS$56K
- Janssen Research & Development, LLC$15K
- plus $30K from 11 others
What the payments were for
- Consulting fees$123,86089%
- Speaking & faculty fees$9,4007%
- Travel & lodging$3,7223%
- Food & beverage$1,9631%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 56 | $382,246 |
| Seagen Inc. | 25 | $275,224 |
| Photocure Inc | 10 | $128,644 |
| Pfizer | 19 | $112,286 |
| Ferring Pharmaceuticals AS | 8 | $56,007 |
| Janssen Research & Development, LLC | 1 | $15,286 |
| Merck | 9 | $7,864 |
| Astellas Pharma Global Development | 3 | $5,900 |
| Janssen Global Services, LLC | 2 | $4,150 |
| Intuitive Surgical | 12 | $4,007 |
| AstraZeneca | 2 | $2,540 |
| Immunitybio, Inc. | 1 | $2,400 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,950 |
| Olympus Winter & Ibe GmbH | 1 | $1,080 |
| Olympus America Inc. | 3 | $169 |
| Johnson & Johnson | 3 | $114 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PADCEV$18,490
- Cysview$13,875
- Da Vinci Surgical System$3,701
- IMFINZI$2,505
- ANKTIVA$2,400
- Single Use Repositionable Clip$1,080
How this compares
$999,885 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 26 | $509 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 23 | $335 |
| Oxybutynin Chloride ErOxybutynin Chloride | 11 | $309 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $47 |
Paid to pharmacies, not to this prescriber.
Other urology in Baltimore
- Ronald TutroneBaltimore$18.1M
- Mohamad AllafBaltimore$7.1M
- Benjamin LowentrittBaltimore$994K
- Kenneth LangerBaltimore$610K
- Arvin GeorgeBaltimore$518K
- Mohummad SiddiquiBaltimore$321K
- Christian PavlovichBaltimore$271K
- Arthur BurnettBaltimore$235K
- Brian MatlagaBaltimore$170K
- Amin HeratiBaltimore$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.